Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results o...

by Schlesinger, Naomi, De Meulemeester, Marc, Pikhlak, Andrey, Yücel, A Eftal, Richard, Dominik, Murphy, Valda, Arulmani, Udayasankar, Sallstig, Peter, So, Alexander
Published 2011

Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis

by Nash, Peter, Vanhoof, Johan, Hall, Stephen, Arulmani, Udayasankar, Tarzynski-Potempa, Rita, Unnebrink, Kristina, Payne, Andrew N., Cividino, Alfred
Published 2016

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

by Burmester, Gerd-Rűdiger, Kivitz, Alan J, Kupper, Hartmut, Arulmani, Udayasankar, Florentinus, Stefan, Goss, Sandra L, Rathmann, Suchitrita S, Fleischmann, Roy M
Published 2015

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

by Alten, Rieke, Gomez-Reino, Juan, Durez, Patrick, Beaulieu, Andre, Sebba, Anthony, Krammer, Gerhard, Preiss, Ralph, Arulmani, Udayasankar, Widmer, Albert, Gitton, Xavier, Kellner, Herbert
Published 2011

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

by Schlesinger, Naomi, Mysler, Eduardo, Lin, Hsiao-Yi, De Meulemeester, Marc, Rovensky, Jozef, Arulmani, Udayasankar, Balfour, Alison, Krammer, Gerhard, Sallstig, Peter, So, Alexander
Published 2011